OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Djouder on the Role of Liver Regeneration in HCC

September 30th 2019

Nabil Djouder, PhD, discusses the role of liver regeneration in hepatocellular carcinoma.

Dr. Greten on the Tumor Microbiome and Antitumor Immunity in Liver Cancer

September 30th 2019

Tim F. Greten, MD, discusses the role of the gut microbiome in antitumor immunity in liver cancer.

Dr. Bekaii-Saab on the APACT Trial in Pancreatic Cancer

September 30th 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the implications of the randomized phase III APACT trial evaluating gemcitabine alone versus gemcitabine plus nab-paclitaxel as adjuvant therapy in patients with pancreatic cancer.

Experts Highlight Anticipated Research to Be Revealed at ESMO 2019

September 29th 2019

OncLive interviewed experts at the State of the Science Summits™ in September 2019 on anticipated research to be presented at the 2019 ESMO Congress.

Dr. Timmerman on Recent Developments in Hodgkin Lymphoma Treatment

September 28th 2019

John M. Timmerman, MD, discusses recent developments made in the treatment of patients with Hodgkin lymphoma.

Dr. Avigan on CAR T-Cell Therapy in Lymphoproliferative Disease

September 28th 2019

David E. Avigan, MD, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.

Dr. Frey on CAR T-Cell Therapy in High-Risk ALL

September 27th 2019

Noelle Frey, MD, MSCE, discusses the use of CAR T-cell therapy in acute lymphocytic leukemia.

Dr. Richards on Secondary Endpoints of the POLO Trial in Pancreatic Cancer

September 27th 2019

Donald A. Richards, MD, PhD, discusses the secondary endpoints of the randomized, double-blind, phase III POLO trial, which evaluated maintenance therapy with olaparib in patients with germline BRCA-mutated, metastatic pancreatic cancer.

Dr. McBride on Biosimilar Rituximab

September 27th 2019

Ali McBride, PharmD, MS, BCOP, discusses the oncology community’s reaction to biosimilars for rituximab (Rituxan).

Dr. Messersmith on Choosing a Treatment Option in mCRC

September 26th 2019

Wells A. Messersmith, MD, discusses therapeutic options in metastatic colorectal cancer and what factors help determine the most appropriate option.

Dr. Tabbara on the Expansion of Treatment Options for AML

September 26th 2019

Imad Tabbara, MD, discusses the expansion of treatment options for patients with acute myeloid leukemia.

Dr. Henderson on Accessibility of Proton Therapy in Prostate Cancer

September 25th 2019

Randal H. Henderson, MD, MBA, discusses accessibility of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

Dr. Wang on Triplet Vorinostat Regimen in Newly Diagnosed MCL

September 25th 2019

Michael Wang, MD, discusses data from a phase I/II study looking at the use a triplet regimen of vorinostat, cladribine, and rituximab in patients with newly diagnosed mantle cell lymphoma.

Dr. Zelenetz on Current Treatment Options for MCL

September 25th 2019

Andrew D. Zelenetz, MD, PhD, discusses approved treatment options for patients with mantle cell lymphoma, as well as treatments coming down the pipeline.

Dr. Marasco on Engineering CAR T Cells

September 25th 2019

Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

Dr. Kohli on the Challenges of Molecular Classification in Prostate Cancer

September 25th 2019

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

Dr. Lenz on Updated Results of the CheckMate-142 Trial in mCRC

September 25th 2019

Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.

Dr. Graff on Current Treatments in ESR1-Mutant Breast Cancer

September 25th 2019

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses current treatments in ESR1-mutant breast cancer.

Dr. Finn on the Rationale for the Phase III KEYNOTE-240 Trial in HCC

September 25th 2019

Richard S. Finn, MD, professor of clinical medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the rationale for the phase III KEYNOTE-240 trial in hepatocellular carcinoma (HCC).

Dr. Lyman on Challenges with Biosimilar Policies

September 25th 2019

Gary H. Lyman, MD, MPH, discusses challenges in biosimilar policies.